Abstract Details

Title Inpatient Hospitalization Risk In Patients With Epilepsy Before And After Perampanel Treatment

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 6-022

Objective

To evaluate inpatient hospitalization risk following initiation of perampanel in patients with epilepsy.

Background

Perampanel, a non-competitive AMPA glutamate receptor antagonist, is approved for the treatment of partial-onset seizures in pediatric and adult patients with epilepsy 4 years of age and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Design/Methods Symphony Health, a nationally representative medical and pharmacy claims database, was used in this study. Patients were identified if they had filled a perampanel prescription during the period July 2014 to June 2016. The index date was the date of the first fill of the medication. Patients were selected if they were 4-11 years old with any partial-onset (focal) seizures (POS), or 12 years of age and above with any POS or any primary generalized tonic–clonic seizures (GTCS), and had continuous observations for the one-year period prior to and following this date. The outcome variables of interest were the one-year all-cause and epilepsy-related relative risk of inpatient hospitalization following perampanel initiation.

Results There were 1,771 patients included in this study. Mean age was 33 years old, 55% are female. Compared to the pre-index period, the post-perampanel period was associated with a significantly lower risk of inpatient hospitalization. The one-year all-cause inpatient hospitalization risk ratio was 0.76 (p < 0.05), with a risk of 36.2% during the pre-index compared to 29.5% in the one year follow-up. Similarly, the one-year epilepsy-related inpatient hospitalization risk ratio was 0.72 (p<0.05), with 30.8% during the pre-index period, compared to 23.9% during the follow-up period.

Conclusions In patients with epilepsy, treatment with perampanel, relative to the one-year period prior to perampanel initiation, was associated with a significant reduction in one-year all-cause and epilepsy-related inpatient hospitalization risk.

Authors/Disclosures
R E. Faught, Jr., MD, FAAN (Emory University) PRESENTER	Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Life Science. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gideon, Essary, Tardio and Carter PLC, Nashville TN TN law firm. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Friedman Dazio and Zulanas Law Firm Birmingham AL. The institution of Dr. Faught has received research support from UCB Pharma. The institution of Dr. Faught has received research support from Cognizance.
Xuan Li (Eisai)	No disclosure on file
	No disclosure on file
Manoj Malhotra, MD	Dr. Malhotra has received personal compensation for serving as an employee of Eisai.
Russell Knoth	No disclosure on file

��ɫ��

��ɫ��